NIH R01 · 2025
Role of Tregs in the acquisition and maintenance of Tconv anergy in transplantation tolerance
Summary Donor-specific transplantation tolerance is an important goal for improving the quality of life of transplant patients, as it eliminates side-effects from chronic immunosuppression. Transient regimens that use a blocking CD154 antibody have been shown to promote donor-specific transplantation tolerance in mice and non-human primates. Although initial clinical trials testing CD154 had been halted due to thromboembolic complications in humans, new humanized Fc-mutated antibodies avoid FcR cross-linking and platelet aggregation and are safe. Three such antibodies are in clinical trials, frexalimab (Sanofi), tegoprubart (AT-1501, Eledon Pharmaceuticals), and TNX-1500, with both…
From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.